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Tumor invasion and metastasis of melanoma have been shown to require proteolytic degradation of the extracellular
environment, achieved primarily by enzymes of the matrix metalloproteinases (MMP) family. Increased enzyme activity
is localized at the border of tumor cells and the adjacent peritumoral connective tissue, emphasizing the crucial role of
tumor–stroma interactions in the regulation of MMP activity. To analyze whether direct cell–cell contacts of melanoma
cells and stromal ﬁbroblasts or whether soluble factors, secreted by melanoma cells are involved in the regulation of
MMP, we used different in vitro co-culture systems. Both direct and indirect co-cultures of high invasive BLMmelanoma
cells and human dermal ﬁbroblasts resulted in an induction of pro-MMP-1 synthesis. Medium conditioned by BLM cells
strongly induced pro-MMP-1 synthesis in ﬁbroblasts, indicating the importance of diffusible factors for this induction.
Competition by recombinant human interleukin (IL)-1 receptor antagonist, neutralizing IL-1a and basic ﬁbroblast growth
factor (bFGF) antibodies, resulted in a concentration-dependent reduction of pro-MMP-1 synthesis. Taken together, our
results indicate an essential role for soluble factors, mainly IL-1a and bFGF, in the stimulation of dermal ﬁbroblasts by
human melanoma cells to secrete MMP-1.
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During invasion and metastasis of melanoma, tumor cells
detach from the primary tumor, migrate, and penetrate sev-
eral structural barriers, e.g. basement membranes and the
interstitial connective tissue, and invade the surrounding
connective tissue of the dermis. A series of studies revealed
that tumor cells are not individual units within a tumor, but
rather depend on the cross-talk with neighboring stromal
cells and matrix components (Hart, 1982; Fidler, 1983;
Liotta et al, 1983; Nicolson, 1987). Of particular importance
are interactions between melanoma cells, the extracellular
environment that includes different matrix constituents,
neighboring fibroblasts, and microvascular endothelial cells.
Although it is well documented that in embryonic develop-
ment various growth factors, cytokines, matrix proteins, and
proteinases act as crucial regulators of mesenchymal–ep-
ithelial cross-talk, increasing evidence suggests that these
regulators are also important in the regulation of tumor
growth. Recent studies with stroma-oriented cancer thera-
py were remarkably successful and are considered as a
particularly promising novel approach for the treatment of
malignancy (Ferrara et al, 2004). Nevertheless, the knowl-
edge in this area is still rudimentary.
The best-characterized proteinases in the degradation of
matrix components are matrix metalloproteinases (MMP)
(Sternlicht and Werb, 2001; Woessner, 2002; Somerville
et al, 2003). Besides regulation of pro-MMP/MMP conver-
sion, the enzyme activity is controlled by the endogenous
inhibitors, tissue inhibitor of metalloproteinases (TIMP). We
have recently shown that the activation of pro-MMP-2 by
MT1-MMP induced by the contact of melanoma cells with
fibrillar type I collagen is differentially regulated, in high and
low invasive cells, by the levels of TIMP-2 (Kurschat et al,
1999). Others have shown that upregulation of TIMP-1 re-
sulted in suppression of in vitro invasive capacity (Khokha
et al, 1992), underlining the importance of MMP in tumor cell
invasion.
In addition, cytokines and growth factors have been
shown to affect cell adhesion and motility, proliferation, and
matrix degradation (Dekker et al, 1997). Among them are
interleukin (IL)-1, IL-8, transforming growth factor-b1 (TGF-
b1), and basic fibroblast growth factor (bFGF), which may
stimulate, in a paracrine fashion, resident cells of the sur-
rounding stroma, e.g. fibroblasts, endothelial cells, keratin-
ocytes, and inflammatory cells leading to enhanced tumor
invasion and angiogenesis (Coussens and Werb, 2002). Re-
cent experiments demonstrated that transduction of the
metastatic melanoma cell line SMEL (constitutively produc-
ing IL-1 at high levels) with IL-1 receptor antagonist (IL-1RA)
results in significant reduction of tumor growth and metas-
tasis to the lungs in nude mice, clearly indicating a role for
Abbreviations: bFGF, basic fibroblast growth factor; EGF, epider-
mal growth factor; IL, interleukin; IL-1RA, IL-1 receptor antagonist;
MMP, matrix metalloproteinase; TGF-b1, transforming growth fac-
tor b1
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IL-1RA in modulating IL-1 activities (Weinreich et al, 2003).
Halaban et al (1988) have shown that the growth of me-
lanoma cells is highly dependent on the production of bFGF
and that the growth was significantly inhibited by injection of
neutralizing anti-bFGF antibodies. Similarly, reduction of
bFGF mRNA expression using an antisense approach could
inhibit melanoma proliferation (Becker et al, 1989).
Several recent investigations have shown that in various
human carcinomas, expression of MMP is localized to both
tumor and stromal cells at the invading margin of the tumor,
providing a mechanism for highly concerted degradation of
the extracellular matrix. Increased expression of MMP-1
has been observed in several carcinomas with the most
abundant expression of MMP-1 observed by the peritu-
moral stromal cells, but significant expression of MMP-1
has also been detected within the tumor by intratumoral
endothelial cells (Johansson et al, 1997). Also in melanoma,
MMP-1 mRNA and protein have been localized to stromal
fibroblasts adjacent to the tumor cells, whereas tumor cells
and fibroblasts distant from the tumor site stained negative
for MMP-1 (Woolley and Grafton, 1980; Airola et al, 1999). In
addition, it has been shown that melanoma patients with
MMP-1- or MMP-3-positive metastases had a significantly
shorter disease-free survival compared with patients with
MMP-1 negative metastases, suggesting that MMP-1 and
MMP-3 may have an important role in the formation of me-
lanoma metastases (Nikkola et al, 2002). In vitro, A2058
melanoma cells were shown not to invade fibrillar type I
collagen unless they were stimulated by fibroblast-condi-
tioned medium (Benbow et al, 1999), suggesting that the
stroma itself has a major impact on the invasive behavior of
tumor cells.
In this work, we have addressed the importance of me-
lanoma–stroma interactions for the induction of proteolytic
enzymes, in particular of MMP-1, and the mediators in-
volved in this cross-talk.
Results
Analysis of MMP-1 synthesis upon co-culture of human
ﬁbroblasts with melanoma cells In order to elucidate the
role of direct or indirect interactions between human dermal
fibroblasts and human melanoma cells in the regulation of
pro-MMP-1 synthesis and activation, we cultured cells ei-
ther in direct or indirect contact using transwell chambers.
We examined two different melanoma cell lines, BLM and
WM164, which we had characterized before in a skin equiv-
alent culture model (Dennhofer et al, 2003). Although BLM
cells were invading the de-epidermized skin, WM164 cells
failed to do so, indicating differences in the ability of tumor
cell invasion. MMP-1 protein levels were completely absent
in BLM and WM164 melanoma cells, and low in monocul-
tures of human dermal fibroblasts (Fig 1). A strong induction
in pro-MMP-1 synthesis, as compared with fibroblast
monoculture, was observed in both direct or indirect co-
cultures with high invasive BLM melanoma cells (Fig 1A). In
contrast, the co-culture of fibroblasts with low invasive
WM164, either in direct or indirect contact, did not alter pro-
MMP-1 synthesis (Fig 1B). To analyze whether the induction
of pro-MMP-1 synthesis observed in the indirect co-culture
requires a cellular cross-talk or whether factors secreted by
melanoma cells are, per se, sufficient to induce protease
expression, we also cultured human fibroblasts in the pres-
ence of melanoma cell-conditioned medium. Treatment of
fibroblasts with increasing concentrations of conditioned
medium was associated with a 4-fold (25% BLM c.m.) and
a 20-fold increase of MMP-1 protein (100% BLM c.m.),
calculated after densitometric analysis as ratio versus un-
treated cells as control (Fig 2A). In contrast, conditioned
media derived from the low invasive WM164 melanoma
cells had no effect on pro-MMP-1 synthesis by fibroblasts
(Fig 2B). These results indicate that soluble factors secreted
by the high invasive melanoma cell line activate stromal
fibroblasts and induce pro-MMP-1 synthesis.
Characterization of soluble factors involved in the in-
duction of pro-MMP-1 synthesis In order to address
which soluble mediators induce pro-MMP-1 synthesis, we
firstly analyzed various cytokines and growth factors for
their capability to induce MMP-1 expression in fibroblasts
grown as monolayer culture for 72 h.
As positive control for the stimulation of the fibroblasts,
we used phorbol 12-myristate 13-acetate (PMA) (0.4 nM),
known to induce pro-MMP-1 synthesis in dermal fibroblasts
(Xu and Clark, 1997). Whereas stimulation with recombinant
IL-6 and epidermal growth factor (EGF) did not alter pro-
MMP-1 synthesis, treatment with recombinant IL-1a, tumor
necrosis factor (TNF)-a, and bFGF strongly induced pro-
MMP-1 synthesis by 2-fold (Fig 3), indicating a potential role
of these soluble factors in the interaction of melanoma cells
and stromal fibroblasts. In contrast, treatment with recom-
binant TGF-b1 and activin reduced pro-MMP-1 synthesis to
levels below untreated control.
Quantification of IL-1a in media conditioned by high or
low invasive melanoma cells and by fibroblasts, using en-
Figure1
Pro-matrix metalloproteinase (MMP)-1 synthesis by fibroblasts is
induced by direct and indirect co-culture of fibroblasts with high
and low invasive melanoma cells. Human dermal fibroblasts (final cell
number of 5  104 cells per cm2, lane 1, and 2.5  104 cells per cm2,
lane 2) and melanoma cells (BLM and WM164; final cell number of
5  104 cells per cm2 (lane 3) were cultured as monolayer. In addition,
fibroblasts and melanoma cells were cultured in direct cell–cell contact
in a 1:1 ratio (final cell number of 5  104 cells per cm2, lane 4) and in a
transwell system (5  104 cells per cm2, lane 5). Co-cultures of BLM
and fibroblasts are shown in (A), whereas co-cultures of WM164 and
fibroblasts are shown in (B).
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zyme-linked immunoassays, detected production of elevat-
ed concentrations of IL-1a (7.8 pg per mL) by the high in-
vasive melanoma cell line BLM and very low production by
the low invasive melanoma cells WM164 and by fibroblasts
(Table I). Also, high amounts of bFGF were secreted by BLM
melanoma cells (392.6 pg per mL), whereas low levels were
detected in the medium conditioned by fibroblasts and by
WM164 cells (Table I).
Inhibition of pro-MMP-1 synthesis by neutralizing IL-1a
and bFGF signalling To analyze the direct involvement of
these factors in the induction of pro-MMP-1 synthesis ob-
served upon treatment of fibroblasts by melanoma cell-
conditioned media, we performed competition assays in the
presence of recombinant IL-1RA (2, 10, and 100 ng per mL),
of neutralizing antibodies against IL-1a (5, 30, and 50 ng per
mL) and against bFGF (10, 50, and 100 mg per mL). Treat-
ment by either recombinant IL-1RA, or by neutralizing anti-
IL-1a and by anti-bFGF antibodies resulted in a concentra-
tion dependent and nearly complete reduction of the 57/52
kDa pro-MMP-1 protein forms, corresponding to 70% in-
hibition as quantitated by densitometric analysis (Fig 4A and
B). Treatment by a combination of both antibodies and IL-
1RA, however, did not further decrease pro-MMP-1 ex-
pression, indicating that in addition to IL-1a and bFGF, other
factors are involved in the induction of pro-MMP-1 synthe-
sis (Fig 4C). In contrast, incubation of fibroblasts by neu-
tralizing anti-IL-6 or anti-EGF antibodies failed to inhibit pro-
MMP-1 synthesis (data not shown).
Figure 2
Western blot analysis of pro-matrix metalloproteinase (MMP)-1
expression. Human dermal fibroblasts (Fb; 5  104 cells per cm2) were
cultured in complete RPMI or in the presence of increasing amounts (%
of the total volume of culture media) of medium conditioned by the
melanoma cells (c.m.). (A) Treatment of Fb with conditioned medium
from high invasive melanoma cells, BLM; (B) treatment of Fb with me-
dium conditioned by low invasive WM164 melanoma cells.
Figure 3
Effect of cytokines and growth factors on pro-matrix metal-
loproteinase (MMP)-1 synthesis by human dermal fibroblasts.
Human dermal fibroblasts were cultured as monolayer in the absence
(Co) or in the presence of recombinant tumor necrosis factor (TNF)-a
(20 ng per mL), epidermal growth factor (EGF) (30 ng per mL), basic
fibroblast growth factor (bFGF) (10 ng per mL), transforming growth
factor-b1 (TGF-b1) (5 ng per mL), interleukin (IL)-6 (100 U per mL), IL-1a
(10 pg per mL), Activin (5 ng per mL), and phorbol 12-myristate 13-
acetate (PMA) (0.4 nM) as described in ‘‘Materials and Methods’’.
Table I. Quantiﬁcation of IL-1a and bFGF in conditioned me-
dium
bFGF (pg per mL) IL-1a (pg per mL)
Fb 77.7  8.2 0
BLM 392.6  55.1 7.8  0.3
WM164 5.9  8.3 0
Levels of bFGF and IL-1a in media, conditioned by Fb and melanoma
cells, BLM, and WM164, were determined using a ELISA, as described
under ‘‘Materials and Methods’’. The data represent the mean  SD of
triplicate experiments. Elevated levels of secreted bFGF and IL-1a were
found in high invasive BLM melanoma cells, as compared with low in-
vasive WM164 cells.
IL, interleukin; bFGF, basic fibroblast growth factor; Fb, fibroblasts.
Figure4
Role of interleukin (IL)-1a and basic fibroblast growth factor (bFGF)
in the induction of pro-matrix metalloproteinase (MMP)-1 synthe-
sis. Human dermal fibroblasts (Fb) were grown in complete RPMI (Co) or
in the presence of 25% complete BLM cells conditioned medium ().
Co-cultures were incubated with increasing concentrations of: (A) re-
combinant IL-1 receptor antagonist (IL-1RA) (2, 10, and 100 ng per mL)
or neutralizing IL-1a monoclonal antibodies (5, 30, and 50 ng per mL); (B)
neutralizing bFGF monoclonal antibodies (10, 50, and 100 mg per mL);
or (C) a combination of IL-1RA, anti-IL-1a, and anti-bFGF (100, 50, and
100 mg per mL, respectively). Additionally, Fb were stimulated with re-
combinant IL-1a (10 pg per mL) and recombinant bFGF (20 ng per mL).
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Distribution of IL-1a in human melanoma tissue Al-
though bFGF expression by melanoma cells in vivo has al-
ready been studied (Reed et al, 1994; Kubo et al, 1998), we
wanted to prove the relevance of IL-1a-mediated activation
of peritumoral fibroblasts by melanoma cells in vivo. There-
fore, we have analyzed cryosections of human melanoma
specimen for the expression of IL-1a (Fig 5). Melanoma and
inflammatory cells were identified by the immunohisto-
chemical staining of the melanoma-specific antigen HMB-
45 and the leukocyte common antigen (LCA), respectively.
IL-1a was strongly expressed in the inflammatory cells
(blue arrows) surrounding the tumor, but also by tumor cells
(black arrows), indicating that both inflammatory and tumor
cells are a source of IL-1a in vivo.
Discussion
A distinguishing feature of malignant cells is their capacity
to invade the surrounding connective tissue, which is a
prerequisite to metastasize through the vascular and lym-
phatic systems to distant organs. It is well established that
tumor cell adhesion, mobility, proteolytic activities, cytokine
secretion, and cell receptor expression play a crucial role in
cancer invasion.
There is increasing evidence that protease expression is
not restricted to neoplastic cells but may also originate from
tumor-associated stromal cells. Using in situ zymography
we have previously shown that the expression of the gel-
atinase MMP-2 is strongly increased in invasive melanomas
when compared with benign melanocytic nevi and that this
activity is localized mainly at the tumor–stroma border and
in the peritumoral stroma (Kurschat et al, 2002).
MMP-1 transcripts were detected at the tumor periphery
of advanced melanomas (Airola et al, 1999), indicating that
MMP-1 may either be derived from the melanoma cells or
the surrounding stromal cells. Wandel et al (2002) have
shown that fibroblasts isolated from the peritumoral stroma
of melanoma display increased synthesis of MMP-1, when
compared with skin fibroblasts distant of the tumor site.
In our studies, we used two different melanoma cells,
which are characterized by different invasive capacity in
nude mice. Both melanoma cell lines did not express MMP-
1 at either transcript or protein levels. In addition, we also
observed no MMP-1 expression by freshly isolated me-
lanoma cells either from primary tumors or from organ
metastases (our unpublished observations). Using different
co-culture systems, we detected increased pro-MMP-1
synthesis in fibroblasts by direct as well as indirect cell–cell
contact with high invasive melanoma cells, whereas un-
stimulated control fibroblasts produced low amounts of this
protease (Fig 1). Interestingly, melanoma cells isolated from
a primary nodular melanoma and from an organ metastasis
showed a similar strong induction of pro-MMP-1 synthesis
in fibroblasts (data not shown). These findings clearly indi-
cate that activation of stromal fibroblasts by high invasive
melanoma cells is caused by soluble factors rather than by
direct cell–cell contacts. Synthesis of pro-MMP-3, which
was previously shown to activate pro-MMP-1 in vitro
(Nagase et al, 1992), was also induced (data not shown).
Under the conditions we used, however, we failed to detect
increased levels of active MMP-1. Relatively high levels of
the endogenous inhibitor, TIMP-1, in both fibroblasts and
BLM cells (Kurschat et al, 1999; Zigrino et al, 2001), might
inhibit the activity of MMP-3 thereby explaining the lack of
activation of MMP-1 we observed. Alternatively, a three-
dimensional environment, which resembles more closely
the in vivo situation, might be needed for proper localization
and activation of the precursor form.
Soluble factors were often suggested to mediate cellular
communication between cancer and stromal cells (Ito et al,
1995; Wandel et al, 2002). Of several soluble factors shown
to induce MMP-1 synthesis in dermal fibroblasts (Yama-
moto et al, 2000; Dasu et al, 2003), here we identified IL-1a
and bFGF as the main melanoma-derived factors inducing
MMP-1 synthesis in fibroblasts. bFGF has recently been
identified as a soluble factor responsible for the activation of
fibroblasts (Wandel et al, 2002). In addition, Graeven et al
(2001) showed that WM164 cells injected in nude mice
failed to form metastases unless overexpressing bFGF or
VEGF. We have measured very low levels of bFGF in culture
media from these low invasive cells, compared with the high
invasive melanoma cells (Table I), correlating with the lack of
pro-MMP-1 induction by low invasive cells. The levels of
different soluble factors and the expression of their recep-
tors have been analyzed in human melanomas in vivo and in
vitro (Herlyn, 1990). Analysis of specific transcripts in 21
melanoma cell and five melanocyte cultures showed that IL-
1a and IL-1-b is expressed by melanoma cells but not by
melanocytes (Mattei et al, 1994).
Besides the role of bFGF, the participation of IL-1a and
IL-1-b in the invasiveness of malignant cells in experimental
tumor models, as well as in cancer patients, has been ex-
tensively studied (Apte and Voronov, 2002). Fibrosarcoma
Figure 5
Distribution of interleukin (IL)-1a in human melanoma tissue. Cryo-
sections (8 mm) of primary melanoma were stained with the HMB-45
antibody identifying melanoma cells (black arrows; as provided) and with
anti-leukocyte common antigen (LCA) localizing the inflammatory infil-
trate (white arrows; 1:100) and anti-IL-1a (10 mg per mL). Magnification,
 100 (upper panel) and  200 (lower panel). Scale bar¼50 mm.
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cells overexpressing IL-1a or IL-1b by transfection were
found to become more aggressive when compared with
mock-transfected cells (Song et al, 2003). Interestingly, us-
ing IL-1a and IL-1b knockout mice, these authors were able
to show that local tumor or lung metastases of B16 me-
lanoma cells were not observed compared with wild-type
animals and that angiogenesis was impaired in these an-
imals. The authors, however, primarily focused on the role of
IL-1 released from tumor cells on the immune response and
did not address changes within the peritumoral stroma
(Voronov et al, 2003).
In our studies, stimulation of fibroblast monocultures with
IL-1a and bFGF induced synthesis of pro-MMP-1, whereas
treatment with TGF-b1 completely abolished the expression
of pro-MMP-1. Other cytokines and growth factors, such as
IL-6 and EGF, failed to alter the expression of this protease
(Fig 3). Competition assays using either recombinant IL-1RA
or neutralizing IL-1a and bFGF antibodies showed that
these factors act in a direct paracrine fashion. Treatment
with a combination of IL-1a and bFGF competitors (Fig 4C),
however, failed to completely inhibit the expression of pro-
MMP-1, thus indicating that other factors might be required
to induce upregulation of pro-MMP-1 in fibroblasts by high
invasive melanoma cells. Future work using array and pro-
teomic technologies will facilitate the identification of addi-
tional factors involved in melanoma-fibroblast cross-talk.
In conclusion, our data support the idea that high inva-
sive melanoma cells can activate stromal fibroblasts to
produce MMP, which in turn facilitate degradation of the
connective tissue and migration of tumor cells into the sur-
rounding connective tissue.
Materials and Methods
Cell culture and preparation of conditioned media Primary hu-
man dermal fibroblasts were obtained by outgrowth from skin ex-
plants as previously described (Zigrino et al, 2001). Cells were
cultured in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal calf serum (FCS), 2 mM glutamine, and 100 U per
mL each of penicillin and streptomycin in 5% CO2, 371C in a hu-
midified atmosphere. Fibroblasts were passaged by trypsinization
at a ratio of 1:2 every 5 d and used at passages 1–10.
The human high invasive and metastatic, BLM (Van Muijen et al,
1991), and the low invasive melanoma cells, WM164 (Herlyn,
1990), were cultured in RPMI 1640 medium supplemented with
10% FCS, 2 mM glutamine, non-essential amino acids, and 100 U
per mL each penicillin and streptomycin (complete medium).
5  104 cells per cm2 were seeded as monolayer for 48 h in
complete RPMI 1640 medium. Cells were washed twice with
phosphate-buffered saline (PBS) and medium replaced by serum-
free RPMI 1640. After 24 h, the medium was collected, centrifuged
at 2000  g for 5 min, to remove cellular debris, and supernatants
were transferred to new tubes. The total protein concentration in
the conditioned medium was determined using the BCA Protein
assay according to the manufacturer’s instructions (Perbio
Science, Bonn, Germany).
The study was approved by the local ethics committee and was
in agreement with the Helsinki Declaration Principles.
Co-culture of melanoma cells and ﬁbroblasts Fibroblasts and
melanoma cells (5  104 cells per cm2) were seeded either as
monocultures or together in a 1:1 ratio as direct co-cultures. Al-
ternatively, both cell types were cultured in indirect co-culture
using transwell cell culture chambers (0.4 mm pore size; Becton
Dickinson, Heidelberg, Germany). To analyze the effect of the me-
lanoma-conditioned medium, fibroblasts were also cultured in the
presence of 25%–100% melanoma-conditioned medium. All cell
culture systems were incubated for 72 h in the above-described
conditions.
Competition assays Fibroblasts were grown in complete RPMI
medium in the presence of recombinant IL-1a (10 pg per mL, Tebu,
Offenbach, Germany) or recombinant bFGF (20 ng per mL, Tebu) or
containing 25% of BLM cells conditioned medium containing
serum. Cells were treated with several concentrations of the re-
combinant IL-1RA (2, 10, and 100 ng per mL, R&D Systems,
Wiesbaden, Germany), neutralizing IL-1a monoclonal antibodies
(5, 30, and 50 ng per mL, R&D Systems), or the neutralizing bFGF
monoclonal antibodies (10, 50, and 100 mg per mL, Upstate, Ham-
burg, Germany) for 48 h. Cells were then washed with PBS and
medium was replaced by either serum-free RPMI or serum-free
BLM cells conditioned medium in the presence of the antagonists
and neutralizing antibodies. After 24 h, supernatants were collect-
ed and processed as described above.
For stimulation, human dermal fibroblasts (Fb; 5  104 cells per
cm2) were cultured in complete RPMI and in the absence or pres-
ence of recombinant TNF-a (20 ng per mL), EGF (30 ng per mL),
bFGF (10 ng per mL), TGF-b1 (5 ng per mL), IL-6 (100 U per mL),
IL-1a (10 pg per mL), activin (5 ng per mL), and PMA (0.4 nM) for 48
h (purchased from Tebu). Cells were then washed with PBS and
incubated for 24 h in serum-free RPMI in the absence or presence
of the cytokines and growth factors as described.
Immunoblot analysis For immunoblot analysis, serum-free con-
ditioned media (corresponding to 20 mg protein) were separated on
10% SDS-PAGE under reducing conditions and transferred to ni-
trocellulose membranes (Hybond C, Amersham, Freiburg, Germa-
ny). After blockage of non-specific-binding sites with 5% non-fat
milk in 0.5% Tween/PBS, blots were incubated with polyclonal
anti-human MMP-1 antibody (diluted 1:2000) (Vallon et al, 1997),
for 1 h at room temperature. Membranes were washed three times
for 7 min in 0.5% Tween/PBS and incubated with porcine anti-
rabbit antibody conjugated to horseradish peroxidase (1:2000
dilution, Dako Envision, Hamburg, Germany) for 1 h at room
temperature. After three washes with 0.5% Tween/PBS solution,
immunoreactive proteins were detected using the ECL western
blotting detection reagents (Amersham) according to the manu-
facturer’s instructions. All experiments were quantified by deter-
mining the signal intensities using ImageQuant software supplied
to ‘‘Personal Densitometer’’ from Molecular Dynamics, Urbana,
Illinois.
ELISA Fibroblasts and melanoma cell-conditioned media were
assayed for protein levels of IL-1a and bFGF. ELISA was performed
according to the manufacturer’s instruction (human IL-1a and hu-
man bFGF, R&D Systems).
The relative amounts of cytokines and growth factors were
calculated according to standard procedures.
Immunohistochemistry Cryosections (8 mm) of primary human
melanoma were fixed in 4% paraformaldehyde in PBS for 15 min,
washed twice with Tris-buffered saline (TBS), followed by blocking
of non-specific-binding sites with 20% FCS/TBS. Primary anti-
bodies were diluted in 10% FCS/TBS and, for IL-1a containing
0.5% saponin (Sigma, Taufkirchen, Germany). Sections were in-
cubated with the primary antibody overnight at 41C. After repetitive
washing, bound antibodies were detected with an alkaline
phosphatase-labelled anti-mouse/anti-rabbit polymer (Dako Envi-
sion) using neofuchsin as a substrate. Nuclei were counterstained
with hematoxylin and mounted with Dako Faramount Aqueous
Mounting Medium (Dako, Hamburg, Germany).
The following antibodies were used: anti-HMB-45 pre-diluted
mouse monoclonal antibody IgG1 (Immunotech, Hamburg, Ger-
many); mouse monoclonal antibody against LCA (clone 2B11;
Dako Envision; final concentration 1:100); and monoclonal anti-
human IL-1a antibody (Clone 4414.141, R&D Systems; final
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concentration 10 mg per mL). Negative controls were performed by
omission of primary antibodies.
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